Comparative Pharmacology
Head-to-head clinical analysis: E Z PREP 220 versus E Z EM PREP LYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E Z PREP 220 versus E Z EM PREP LYTE.
E-Z PREP 220 vs E-Z-EM PREP LYTE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Bisacodyl is a diphenylmethane stimulant laxative that acts directly on colonic mucosa to stimulate sensory nerve endings, increasing peristalsis and colonic motility. It also inhibits water and electrolyte absorption in the small intestine and colon, leading to increased fluid accumulation and defecation.
Polyethylene glycol (PEG) 3350 is an osmotic laxative that induces diarrhea by retaining water in the bowel, thereby cleansing the colon. Electrolytes (sodium sulfate, sodium chloride, potassium chloride) are added to prevent electrolyte imbalance.
FDA-approved: Bowel cleansing prior to colonoscopy or other medical procedures.Off-label: Treatment of acute constipation.
Bowel cleansing prior to colonoscopyBowel preparation for barium enemaOff-label: Management of constipation
Adult: 2.25 g (3 tablets of 750 mg each) orally, divided into two doses (1.5 g each) on the day before colonoscopy, with the second dose 6 hours before the procedure. Alternatively, 750 mg orally twice daily for 2 days prior. Route: oral. Frequency: as a split-dose or two-day regimen.
Oral: 4 liters as a single dose for colonoscopy preparation.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (prolonged in renal impairment; no dose adjustment required for mild-moderate impairment but caution in severe forms).
The terminal elimination half-life of PEG 3350 is approximately 4-6 hours; clinical effects are largely non-systemic due to minimal absorption.
Bisacodyl is primarily metabolized in the liver via glucuronidation to inactive metabolites. It undergoes enterohepatic recirculation and is excreted in feces and urine.
PEG 3350 is not significantly metabolized; it is excreted unchanged in feces. Electrolytes are absorbed or excreted via renal and gastrointestinal pathways.
Renal: 60% as unchanged drug; Fecal: 30% (biliary elimination of glucuronide conjugates); Other: 10% metabolized via hepatic oxidation.
Renal elimination of absorbed polyethylene glycol (PEG) is approximately 50-70% unchanged; the remainder is excreted in feces. Electrolytes are absorbed and renally excreted.
99% bound primarily to albumin; also binds to alpha-1-acid glycoprotein with lower affinity.
PEG 3350: negligible protein binding (<1%); no specific binding proteins identified.
Vd: 0.15-0.3 L/kg (indicating limited extravascular distribution consistent with high protein binding).
Vd for PEG 3350 is approximately 0.2-0.3 L/kg; reflects distribution primarily in extracellular fluid with minimal tissue penetration.
Oral: 45-55% (due to first-pass metabolism; food increases bioavailability by ~20%).
Oral bioavailability of PEG 3350 is approximately 10-20% due to minimal gastrointestinal absorption; electrolytes are absorbed systemically.
Contraindicated in patients with eGFR <30 mL/min/1.73 m². For eGFR 30–59 mL/min/1.73 m², use with caution; consider reducing dose to 1.5 g (2 tablets) total, administered as a split dose.
Contraindicated in patients with GFR < 30 mL/min; for GFR 30-60 mL/min, use with caution and ensure adequate hydration.
Child-Pugh Class A: No adjustment needed. Child-Pugh Class B: Use with caution; consider reducing dose to 1.5 g total. Child-Pugh Class C: Not recommended due to risk of fluid overload and electrolyte disturbances.
No specific adjustment for Child-Pugh class A or B; for class C, use only if benefits outweigh risks due to potential for fluid overload.
Not approved for pediatric use (safety and efficacy not established).
Not indicated for patients under 18 years of age.
Elderly patients: Use with caution due to increased risk of fluid and electrolyte imbalances and renal impairment. Consider dose reduction to 1.5 g total, and ensure adequate hydration.
Use with caution due to increased risk of aspiration and electrolyte imbalance; consider split-dose regimen.
No FDA boxed warning exists for this drug.
No FDA black box warning.
Use with caution in patients with acute surgical abdomen, intestinal obstruction, or undiagnosed abdominal pain. May cause electrolyte disturbances (e.g., hypokalemia, hypermagnesemia) with prolonged use. Avoid use in patients with renal impairment due to risk of hypermagnesemia. Do not use for >7 days unless directed by a physician.
["Risk of electrolyte abnormalities (e.g., hypernatremia, hypokalemia) in patients with renal impairment or those taking diuretics","Aspiration risk, especially in patients with impaired gag reflex or swallowing disorders","Use caution in patients with colitis, toxic megacolon, or gastrointestinal obstruction","Potential for cardiac arrhythmias due to electrolyte shifts","Dehydration and fluid overload risk in elderly or debilitated patients"]
Absolute: Known hypersensitivity to bisacodyl; intestinal obstruction; acute surgical abdomen; peritonitis; appendicitis; rectal fissures; ulcerative colitis; severe dehydration. Relative: Pregnancy (use only if clearly needed); lactation; use in children <6 years old.
["Gastrointestinal obstruction or perforation","Ileus or toxic megacolon","Severe renal impairment (e.g., creatinine clearance <30 mL/min)","Known hypersensitivity to any component","Active severe colitis"]
Data Pending Review
Data Pending Review
Avoid solid foods, milk, and fruit/vegetable juices with pulp. Do not consume red, purple, or blue liquids. Permitted clear liquids: water, clear broth, black coffee, tea, clear fruit juices (apple, white grape), gelatin, popsicles without fruit or cream.
Avoid all solid foods, milk, and red or purple liquids (e.g., grape juice, Jell-O) during preparation. Only clear liquids allowed: water, clear broth, apple juice, clear sodas, black coffee or tea (no milk), and clear gelatin (no fruit).
FDA Pregnancy Category C. First trimester: Risk of fetal malformations not definitively established; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: No documented fetal harm; crosses placenta minimally. Avoid in late pregnancy near term due to potential for maternal-fetal electrolyte disturbances.
E-Z-EM PREP LYTE is a balanced electrolyte solution (sodium sulfate, magnesium sulfate, potassium chloride) for colonoscopy preparation. There are no adequate and well-controlled studies in pregnant women. Animal studies are not available. The risk of electrolyte imbalance and dehydration may increase fetal risk if used improperly. In the first trimester, theoretical risks from electrolyte shifts; second and third trimesters, risk of maternal dehydration leading to reduced placental perfusion. Use only if clearly needed.
Excreted into breast milk in trace amounts; M/P ratio not determined. Considered compatible with breastfeeding in single doses. Use caution with repeated dosing due to potential for osmotic diarrhea in infant.
No human data on excretion in breast milk. Electrolytes (sodium, potassium, magnesium) are normal milk constituents. M/P ratio unknown. While systemic absorption is minimal, consider risks of maternal dehydration or electrolyte imbalance. Use with caution in nursing mothers.
No standard dose adjustment required for single-use bowel preparation. Consider reduced dose or alternative if severe morning sickness or hyperemesis gravidarum due to electrolyte shift risk. Pharmacokinetic changes in pregnancy (increased plasma volume, GFR) may necessitate lower volume but no specific dose modification established.
No specific dosing adjustments for pregnancy; standard dose (3 liters) may be used but with caution due to increased risk of dehydration and electrolyte disturbances. Consider reduced dose or split-dose in pregnant patients. Monitor closely.
Category C
Category C
E-Z PREP 220 contains 220 grams of polyethylene glycol 3350 for bowel cleansing. Administer in two doses: first dose at 6 PM, second at 9 PM the evening before colonoscopy. Ensure adequate hydration; patient must consume clear liquids after starting prep. Monitor for bloating, nausea, vomiting; slow or stop if intolerant. Contraindicated in GI obstruction, ileus, or severe renal impairment (CrCl <30 mL/min).
E-Z-EM PREP LYTE is a polyethylene glycol (PEG)-based bowel preparation for colonoscopy. Ensure adequate hydration before, during, and after use to prevent electrolyte imbalance. Administer in divided doses per protocol. Monitor for nausea, bloating, or aspiration risk in elderly or debilitated patients. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
Take the first dose at 6 PM and the second dose at 9 PM the night before your procedure.Only consume clear liquids after starting the prep; no solid foods, milk, or red/purple liquids.Drink additional clear liquids to stay hydrated; each dose should be mixed with 32 ounces of water.Expect diarrhea; stay near a bathroom. If you experience severe bloating or vomiting, stop and contact your doctor.Do not take other laxatives or medications within 1 hour of taking this prep.
Do not eat solid food from the start of preparation until after the procedure. Consume only clear liquids.Mix the powder with water as directed and refrigerate for better taste. Do not add other flavors or sweeteners.Drink the entire amount over the prescribed time. For 4-liter preparation, drink 8 ounces every 10-15 minutes.Expect watery stools, which indicate effective cleansing. Stay near a restroom.If severe bloating, abdominal pain, vomiting, or inability to tolerate the solution occurs, contact your doctor.